![Kevin Bruce](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kevin Bruce
Director de Operaciones en Censo Biotechnologies Ltd. .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Liam Taylor | M | 47 |
Censo Biotechnologies Ltd.
![]() Censo Biotechnologies Ltd. Miscellaneous Commercial ServicesCommercial Services Censo Biotechnologies Ltd. operates as stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. It offers human bio-sample procurement, IPSC generation & genome editing, IPSC differentiation, assay development and screening services. The company is headquartered in Midlothian, the United Kingdom. | - |
Derek Trezise | M | - |
Censo Biotechnologies Ltd.
![]() Censo Biotechnologies Ltd. Miscellaneous Commercial ServicesCommercial Services Censo Biotechnologies Ltd. operates as stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. It offers human bio-sample procurement, IPSC generation & genome editing, IPSC differentiation, assay development and screening services. The company is headquartered in Midlothian, the United Kingdom. | - |
Oliver Richardson | M | 29 |
Censo Biotechnologies Ltd.
![]() Censo Biotechnologies Ltd. Miscellaneous Commercial ServicesCommercial Services Censo Biotechnologies Ltd. operates as stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. It offers human bio-sample procurement, IPSC generation & genome editing, IPSC differentiation, assay development and screening services. The company is headquartered in Midlothian, the United Kingdom. | - |
Tom Stratford | M | 54 |
Censo Biotechnologies Ltd.
![]() Censo Biotechnologies Ltd. Miscellaneous Commercial ServicesCommercial Services Censo Biotechnologies Ltd. operates as stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. It offers human bio-sample procurement, IPSC generation & genome editing, IPSC differentiation, assay development and screening services. The company is headquartered in Midlothian, the United Kingdom. | - |
Dean Morris | M | - |
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | 1 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Peter Coleman | M | 57 |
Roslin Cell Therapies Ltd.
![]() Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | 1 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Reino Unido | 6 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Kevin Bruce
- Red Personal